Oral CBD/CBG hemp extract reduced ulcerative colitis severity and pain in mice
A commercial hemp extract high in CBG and CBD reduced colonic tissue damage and pain responses in a mouse model of ulcerative colitis when administered orally.
Quick Facts
What This Study Found
Cannabinoid treatment reduced damage to the colonic epithelium and decreased pain-related responses in DSS-induced colitis mice. Oral administration was effective, suggesting potential for a practical delivery route.
Key Numbers
Hemp extract high in CBG and CBD. Two administration routes tested (i.p. and oral). Both routes showed efficacy for colonic protection and pain reduction.
How They Did This
DSS-induced ulcerative colitis mouse model treated with a commercial hemp extract high in CBG and CBD via two routes: intraperitoneal and oral. Colonic tissue damage and pain behaviors were assessed.
Why This Research Matters
Most cannabinoid-colitis research uses purified compounds or intraperitoneal injection. This study tested a practical oral hemp extract, making findings more relevant to real-world supplementation, though animal-to-human translation remains uncertain.
The Bigger Picture
CBG is increasingly recognized as a potentially important cannabinoid for gastrointestinal conditions. Combined with the CBD/CBDV colitis study (RTHC-06519), evidence is building that cannabinoid combinations may be more effective than single compounds for inflammatory bowel conditions.
What This Study Doesn't Tell Us
Animal model using chemical (DSS) induction, not spontaneous colitis. Commercial extract means exact composition may vary between batches. Limited detail on dosing and outcome quantification in the abstract.
Questions This Raises
- ?How does the CBG/CBD combination compare to CBD alone for colitis?
- ?Would this hemp extract show similar benefits in a chronic colitis model?
Trust & Context
- Key Stat:
- hemp extract reduced colonic tissue damage and pain responses in ulcerative colitis mice via a practical oral route
- Evidence Grade:
- Preliminary animal study with practical oral delivery route, but limited outcome detail and chemical colitis model reduce strength.
- Study Age:
- 2025 publication.
- Original Title:
- Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model.
- Published In:
- Journal of clinical medicine, 14(17) (2025)
- Authors:
- Godbole, Shivani S, Sun, Dongxiao, Coates, Matthew D(4), Himmelberger, Victoria J, Roopchand, Diana E, Raup-Konsavage, Wesley M
- Database ID:
- RTHC-06551
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CBG?
Cannabigerol (CBG) is a non-psychoactive cannabinoid found in cannabis, sometimes called the "mother cannabinoid" because other cannabinoids are synthesized from its acidic form. It has shown anti-inflammatory properties in preliminary research.
Why test a commercial extract instead of pure compounds?
Commercial extracts are what consumers actually use. Testing them directly is more relevant to real-world applications than purified compounds, though it makes it harder to identify which specific components are responsible for effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06551APA
Godbole, Shivani S; Sun, Dongxiao; Coates, Matthew D; Himmelberger, Victoria J; Roopchand, Diana E; Raup-Konsavage, Wesley M. (2025). Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model.. Journal of clinical medicine, 14(17). https://doi.org/10.3390/jcm14176095
MLA
Godbole, Shivani S, et al. "Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14176095
RethinkTHC
RethinkTHC Research Database. "Orally Administered CBD/CBG Hemp Extract Reduces Severity of..." RTHC-06551. Retrieved from https://rethinkthc.com/research/godbole-2025-orally-administered-cbdcbg-hemp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.